IMAB
Price
$0.92
Change
-$0.03 (-3.16%)
Updated
Dec 18, 04:16 PM (EDT)
98 days until earnings call
RAPT
Price
$0.82
Change
-$0.02 (-2.38%)
Updated
Dec 18, 04:59 PM (EDT)
78 days until earnings call
Ad is loading...

IMAB vs RAPT

Header iconIMAB vs RAPT Comparison
Open Charts IMAB vs RAPTBanner chart's image
I-MAB
Price$0.92
Change-$0.03 (-3.16%)
Volume$111
CapitalizationN/A
RAPT Therapeutics
Price$0.82
Change-$0.02 (-2.38%)
Volume$8.42K
CapitalizationN/A
IMAB vs RAPT Comparison Chart
Loading...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RAPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMAB vs. RAPT commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMAB is a Hold and RAPT is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (IMAB: $0.95 vs. RAPT: $0.84)
Brand notoriety: IMAB and RAPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMAB: 48% vs. RAPT: 65%
Market capitalization -- IMAB: $77.04M vs. RAPT: $29.4M
IMAB [@Biotechnology] is valued at $77.04M. RAPT’s [@Biotechnology] market capitalization is $29.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMAB’s FA Score shows that 0 FA rating(s) are green whileRAPT’s FA Score has 0 green FA rating(s).

  • IMAB’s FA Score: 0 green, 5 red.
  • RAPT’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMAB and RAPT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMAB’s TA Score shows that 4 TA indicator(s) are bullish while RAPT’s TA Score has 5 bullish TA indicator(s).

  • IMAB’s TA Score: 4 bullish, 4 bearish.
  • RAPT’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both IMAB and RAPT are a good buy in the short-term.

Price Growth

IMAB (@Biotechnology) experienced а -10.82% price change this week, while RAPT (@Biotechnology) price change was -22.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

IMAB is expected to report earnings on Mar 26, 2025.

RAPT is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMAB($77M) has a higher market cap than RAPT($29.4M). IMAB YTD gains are higher at: -50.247 vs. RAPT (-96.615). RAPT has higher annual earnings (EBITDA): -113.61M vs. IMAB (-212.17M). IMAB has more cash in the bank: 184M vs. RAPT (97.9M). IMAB has less debt than RAPT: IMAB (3.78M) vs RAPT (5.12M). IMAB has higher revenues than RAPT: IMAB (3.27M) vs RAPT (0).
IMABRAPTIMAB / RAPT
Capitalization77M29.4M262%
EBITDA-212.17M-113.61M187%
Gain YTD-50.247-96.61552%
P/E RatioN/AN/A-
Revenue3.27M0-
Total Cash184M97.9M188%
Total Debt3.78M5.12M74%
TECHNICAL ANALYSIS
Technical Analysis
IMABRAPT
RSI
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 9 days ago
78%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RAPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IKT3.970.40
+11.20%
Inhibikase Therapeutics
KALA6.190.08
+1.31%
Kala BIO
EFX273.670.17
+0.06%
Equifax
PRIM80.87-0.99
-1.21%
Primoris Services Corp
REVG32.60-1.57
-4.59%
REV Group

IMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMAB has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IMAB jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
-1.47%
VCYT - IMAB
43%
Loosely correlated
-2.52%
CTMX - IMAB
32%
Poorly correlated
-1.74%
RAPT - IMAB
31%
Poorly correlated
-4.56%
ARRY - IMAB
31%
Poorly correlated
+6.01%
AVXL - IMAB
29%
Poorly correlated
+0.33%
More